To examine the change in immune balance during the treatment of patients with chronic hepatitis B with entecavir and thymosin a1, we further analyzed the expression of immune factors such as IL-6, IL-12, IFN-γ, and TNF-α at the 12th, 24th, and 48th week of treatment cycles. The gene discussed is IFNG; the disease is chronic hepatitis B virus infection.